SK Chemical signs a joint sales agreement with Viatris

for three of Viatris’ original products

Expand its line-up of pain medications, including Celebrex, Neurontin, and Lyrica.

SK Chemicals, which developed the first natural drug for osteoarthritis in Korea, ‘Joins Tab,’ has secured additional pain medications for its portfolio.

 

SK Chemical (CEO Jae-Hyun Ahn) announced on the 5th that it has signed a distribution and sales agreement with Viatris Korea for △Lyrica, △ Neurontin, and △ Celebrex.

 

Under the agreement, SK Chemicals will be responsible for the distribution of the three drugs to all hospitals and marketing to hospitals and clinics with less than 300 beds.

 

Marketing to general hospitals with more than 300 beds will be handled by Viatris Korea.

 

△ 'Lyrica', a treatment for peripheral and central neuropathic pain △ 'Neurontin', a treatment for neuropathic pain △ 'Celebrex', an anti-inflammatory analgesic, are products whose efficacy and safety have been confirmed through various clinical studies.

 

SK Chemicals plans to maximize synergies with its existing products, such as ‘Joins’ and ‘Ultracet,’ by expanding its lineup of pain treatment products through this agreement.

 

In the case of the osteoarthritis treatment drug, Joins, which is SK Chemicals' representative pain medication, and the non-narcotic anti-inflammatory analgesic drug, Ultracet, which is exclusively sold by SK Chemicals, the two are actively used in combination with the three Viatris products, so the collaboration is expected to bring synergy between the products.

 

Hyunsun Park, Head of the Pharma Business at SK Chemicals, said, “The introduction of Lyrica, Neurontin, and Celebrex will provide patients and medical staff with a wider range of effective pain treatment options.

 

We will continue to secure new pipelines that are highly linked to existing businesses and strengthen our expertise in specialized markets such as pain treatments.”